FDAnews
www.fdanews.com/articles/196691-new-hydroxychloroquine-trial-data-show-little-benefit

New Hydroxychloroquine Trial Data Show Little Benefit

April 16, 2020

New clinical trial data from China suggest that hydroxychloroquine may not be a useful treatment for COVID-19 patients.

The study of 150 hospitalized COVID-19 patients found that adding the antimalarial drug did not improve upon the standard-of-care.

The malaria drug did appear to reduce inflammation, but more adverse events were observed in the hydroxychloroquine group vs. the standard-of-care cohort.

Sanford Health, a rural nonprofit health care system in South Dakota, announced Monday that it is leading a trial of hydroxychloroquine in 2,000 outpatients exposed to COVID-19 (DID, April 14).

Access details of the China study here: bit.ly/2xAaMIb. — Jordan Williams